期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

帕金森病的新药治疗 被引量：7

原文传递
导出
摘要 帕金森病（PD）是一种中枢神经系统锥体外系功能障碍的慢性进行性疾病，临床表现为肌肉震颤、僵直、姿势障碍、运动困难等。药物治疗仍是目前最主要的方法。多年来人们一直致力于PD新药的研发，取得了较大进展。本研究就目前的新药治疗进展作一综述。
作者 张海娜 陈秋惠 胡国华
机构地区 吉林大学第二临床医院神经内科
出处 《中国基层医药》 CAS 2009年第10期1919-1920,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 药物治疗 帕金森病 新药 锥体外系功能障碍 慢性进行性疾病 中枢神经系统 肌肉震颤 临床表现
分类号 R742 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献14

  • 1Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Curr Opin Investig,2006,7( 1 ) :25-32.
  • 2崔银珠.多巴胺促进剂罗匹尼罗是治疗帕金森的一线药物[J].国外医药：合成药．生化药．制剂分册,2000,21(2):119-119.
  • 3Rased O, Brooks D J, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations: a randomised, double-blind, parallel-group trial. Lancet, 2005,365 ( 9463 ) : 947 -954.
  • 4Guay DR. Rasagiline(TVP-1012) :a new selective monoamine oxldaze inhibitor for Parkinson's disease. Geriatric Am J Geriatr Pharmacother,2006,4 (4) :330-346.
  • 5Agid Y. Entacapone to tolcapone switch : multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov Disord,2006,22( 1 ) :14-19.
  • 6保明利,张林霞.41例病毒性心肌炎回顾分析[J].中国基层医药,2003,10(6):525-525. 被引量：3
  • 7Clifford WS. Therapeutic role of coenzyme Q10 in Parkinson's disease. Pharmacol Ther,2005,1 ( 107 ) : 120-130.
  • 8Hallett PJ,Standaert DG. Rationale for and use of NMDA receptor antagonists in Parkinson' s disease. Pharmacol Ther, 2004, 102 (2) :155-174.
  • 9Savola JM, Hill M, Engstrom M, et al. Fipamezole (JP21730) is apotent alpha-adrenergic receptor antagonist that reduces levodopainduced dyskinesia in the MPTP-lesione primate model of Parkinson's disease. Mov Disord ,2003,18 (8) :872-883.
  • 10Hanser RA, Hubble JP, Truong DD, et al. Randomized trial of the adenosine A ( 2A ) receptor antagonist istradefylline in advanced PD. Neurology,2003,61 (3) :297-303.

二级参考文献27

  • 1Giladi N, TrevesTA, Simon ES, et al. Freezing of gait in patients with advanced Parkinson's disease[J]. J Neural Transm, 2001,108:53.
  • 2Lingor P, Unsicker K, Krieglstein K. GDNF and NT-4 protect midbrain dopaminergic neurons from toxic damage by iron and nitric oxide[J]. Exp Neurol, 2000,63: 55.
  • 3Delanty N, Dichter MA. Antioxidant therapy in neurologic disease[J]. Arch Neurol, 2000,57: 1265.
  • 4Doble A. The role of excitotoxicity in neurodegenerative disease: Implications for therapy[ J ]. Pharmacol Ther, 1999,81: 163.
  • 5Shoulson 1, Penney J, McDermott M, et al. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease[J]. Neurology, 2001,56(4):455.
  • 6Factor SA, Molho ES. Transient benefit of amantadine in Parkinson's disease: The facts about the myth[J]. Mov Disord, 1999,14:515.
  • 7A controlled trial of recombinant methionyl human BDNF in ALS:The BDNF Study Group (Phase Ⅲ)[J]. Neurology, 1999,52:1427.
  • 8Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase[J]. Nat Genet,2000,25(3):302.
  • 9Hohhoff VA, Vieregge P, Kessler J, et al. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits[J]. Ann Neurol, 1994, 36(2) :176- 182.
  • 10Yoshino H, Hattori Y, Imai H, et al. Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease[J]. Rinsho Shinkeigaku, 1993, 33(3):261- 265.

共引文献21

同被引文献98

引证文献7

二级引证文献35

中国基层医药
2009年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部